NICE Single Technology Appraisal Guidance
No 221 – Romiplostim for the
treatment of thrombocytopenic purpura
This NICE Guidance was published today,27 April
2011. The web reference for the appraisal and other related
documents is: www.nice.org.uk/TA221
NHSScotland should note
that:
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHS Scotland.
2. NHS Boards should continue to adhere to the
SMC advice.
The Scottish Medicines Consortium (SMC)
published a Statement of Advice (553/09) on this medication for
this indication in October 2009. This stated that:
Romiplostim (Nplate®) is accepted for
restricted use within NHS Scotland for adult chronic immune
(idiopathic) thrombocytopenic purpura (ITP) splenectomised patients
who are refractory to other treatments (e.g. corticosteroids,
immunoglobulins). Romiplostim is also accepted for restricted
use as second line treatment for adult non-splenectomised patients
where surgery is contra-indicated. Romiplostim is restricted to use
in patients with severe symptomatic ITP or patients with a high
risk of bleeding.
Access the advice of the Scottish Medicines Consortium
3. There is no material difference between the
recommendations of the NICE STA and the SMC. The NICE STA advice is
based upon the application of a Department of Health agreed Patient
Access Scheme.
If you need further assistance, please contact
Eleanor Brownlee in
the first instance tel 0141 225 6873
Published Date: 27 April 2011
